The power of scientific and technological innovation
Our laboratory is based on the forefront of molecular diagnosis, actively conducts research in the field of global scientific research, and uses advanced scientific research equipment to achieve growth in results to promote the development of science.
The power of scientific and technological innovation
Based in China and facing the world
8000
+
sqm corporate headquarters
4000
+
square meters GMP standardized factory building
77
+
Intellectual property rights
1
+
Medical Laboratory Practice
2
+
Global R&D Center
3
+
Global Biolabs
Innovation Areas
Pathogen Detection
Infection Detection
Pregene Biotechnology has designed and optimized specific detection reagents for common pathogenic microorganisms in different clinical syndromes and highly virulent microorganisms that are of clinical focus. It uses NeoHiT® PCR technology to detect multiple pathogenic microorganisms at the same time.
01
Tumor Diagnosis
Infection Detection
Combined with NeoHiT® PCR, Pregene Biotechnology has developed molecular diagnostic products that can simultaneously detect multiple specific biomarkers for tumors in different tissues and at different stages of development, which can provide clinical services ranging from early tumor screening, clinical auxiliary diagnosis, Molecular diagnostic support for multiple different application directions such as targeted drug companion diagnostics and prognosis dynamic monitoring.
02
Reproductive Health
Infection Detection
Reproductive health-related diagnosis requires extremely high accuracy, and the samples available are relatively rare and valuable. The clinical diagnosis solution for reproductive health developed by Pregene Biotechnology takes full advantage of the high detection throughput of NeoHiT® PCR to conduct repeated multi-target detection of nucleic acid fragments of rare samples, thereby quickly and accurately obtaining reproductive health information such as chromosome copy number. Genetic-related key information leaves sufficient time for further clinical decision-making.
03
